The role of saliva in oral health: strategies for prevention and management of xerostomia.
Oral complications are the most frequent and debilitating sequelae of radiation treatment for patients with head and neck cancer. Impaired salivary function and consequent xerostomia can persist for years after radiation treatment, significantly increasing the risk of oral and dental disease and negatively affecting patients' quality of life. Current evidence indicates that many patients undergoing radiation treatment do not receive adequate oral and dental care and follow-up and that patients' compliance with oral care recommendations is frequently poor. Topical lubricants, coating agents,and saliva substitutes or lozenges may provide transient relief from xerostomia. Cholinergic stimulants such as pilocarpine improve salivary flow but have had mixed results in improving patients' assessments of symptoms or other quality-of-life measures. Advances in radiotherapy techniques, such as intensity-modulated radiation therapy, have enabled increased delivery of therapeutic doses of radiation to tumors while limiting exposure to normal tissues, thereby reducing the incidence, duration, and severity of xerostomia in some patients with head and neck cancers. Additionally, radioprotective agents such as amifostine have been shown to reduce radiation-induced toxicity to normal tissues within the radiation field. Studies are ongoing to determine the optimal approaches for these techniques and agents to maximize clinical response while improving the overall quality of life for patients with head and neck cancer.
Brosky
Mary Elizabeth
ME
Maxillofacial Prosthodontic Clinic, University of Minnesota School of Dentistry, Minneapolis 55455, USA. brosk001@umn.edu
D000970:Antineoplastic Agents / Q000009:adverse effects; D003729:Dental Care; D004307:Dose-Response Relationship, Radiation; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D009909:Oral Health; D011788:Quality of Life; D011832:Radiation Injuries / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D012463:Saliva / Q000187:drug effects / Q000528:radiation effects; D014987:Xerostomia / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control* / Q000628:therapy
D000970:Antineoplastic Agents; D011837:Radiation-Protective Agents